Walleye Capital’s Sana Biotechnology SANA Stock Holding History

Walleye Capital’s Portfolio SANA Stock Details SANA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-77,080	Closed	-$274K	–	5051
2025 Q3	$274K	Buy	+77,080	New	+$279K	﹤0.01%	3088
2025 Q1	–	Sell	-93,383	Closed	-$152K	–	5029
2024 Q4	$152K	Buy	+93,383	New	+$278K	﹤0.01%	3922

Other funds holding SANA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Walleye Capital's SANA Position: Q4 2025 in Review

Walleye Capital sold out of Sana Biotechnology (SANA) in Q4 2025, closing a stake of 77,080 shares — an estimated $274K sold.

Walleye Capital first reported a position in SANA in Q4 2024 and held it in 2 quarters. The position peaked at $274K in Q3 2025. 203 funds tracked by Wall St. Rank hold SANA as of Q4 2025.

Walleye Capital reported no remaining Sana Biotechnology position as of Q4 2025 after selling out during the quarter.
Walleye Capital sold 77,080 Sana Biotechnology shares in Q4 2025, an estimated $274K.
Walleye Capital first reported a position in Sana Biotechnology in Q4 2024 and held it in 2 quarters.
Walleye Capital's Sana Biotechnology position peaked at $274K in Q3 2025.
203 funds tracked by Wall St. Rank held Sana Biotechnology as of Q4 2025.

Based on Walleye Capital's 13F filing for Q4 2025, filed 13 Feb 2026.